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A bs tr ac t
Background
There is no consensus regarding the safety and efficacy of drug-eluting stents, as 
compared with bare-metal stents, in patients with ST-segment elevation myocardial 
infarction who are undergoing primary percutaneous coronary intervention (PCI).
Methods
We randomly assigned, in a 3:1 ratio, 3006 patients presenting with ST-segment eleva-
tion myocardial infarction to receive paclitaxel-eluting stents (2257 patients) or other-
wise identical bare-metal stents (749 patients). The two primary end points of the 
study were the 12-month rates of target-lesion revascularization for ischemia (analysis 
powered for superiority) and a composite safety outcome measure of death, reinfarc-
tion, stroke, or stent thrombosis (powered for noninferiority with a 3.0% margin). 
The major secondary end point was angiographic evidence of restenosis at 13 months.
Results
Patients who received paclitaxel-eluting stents, as compared with those who received 
bare-metal stents, had significantly lower 12-month rates of ischemia-driven target-
lesion revascularization (4.5% vs. 7.5%; hazard ratio, 0.59; 95% confidence interval 
[CI], 0.43 to 0.83; P = 0.002) and target-vessel revascularization (5.8% vs. 8.7%; hazard 
ratio, 0.65; 95% CI, 0.48 to 0.89; P = 0.006), with noninferior rates of the composite 
safety end point (8.1% vs. 8.0%; hazard ratio, 1.02; 95% CI, 0.76 to 1.36; absolute 
difference, 0.1 percentage point; 95% CI, −2.1 to 2.4; P = 0.01 for noninferiority; 
P = 0.92 for superiority). Patients treated with paclitaxel-eluting stents and those treat-
ed with bare-metal stents had similar 12-month rates of death (3.5% and 3.5%, 
respectively; P = 0.98) and stent thrombosis (3.2% and 3.4%, respectively; P = 0.77). The 
13-month rate of binary restenosis was significantly lower with paclitaxel-eluting 
stents than with bare-metal stents (10.0% vs. 22.9%; hazard ratio, 0.44; 95% CI, 
0.33 to 0.57; P<0.001).
Conclusions
In patients with ST-segment elevation myocardial infarction who were undergoing 
primary PCI, implantation of paclitaxel-eluting stents, as compared with bare-metal 
stents, significantly reduced angiographic evidence of restenosis and recurrent ische-
mia necessitating repeat revascularization procedures. No safety concerns were ap-
parent at 1 year. (ClinicalTrials.gov number, NCT00433966.)
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By enlarging luminal dimensions and sealing dissection planes at the site of coronary-artery occlusion in patients with 
evolving ST-segment elevation myocardial infarc-
tion, bare-metal stents reduce the risk of early and 
late recurrent ischemia and reocclusion of the 
infarct-related artery, as compared with balloon 
angioplasty alone, decreasing the need for subse-
quent revascularization of the target lesion with 
repeat percutaneous coronary intervention (PCI) 
or coronary-artery bypass grafting.1,2 Nonetheless, 
restenosis occurs in more than 20% of patients 
in whom bare-metal stents are implanted during 
primary PCI, and implantation of bare-metal 
stents, as compared with balloon angioplasty, has 
not reduced the rates of death or reinfarction 
among patients with ST-segment elevation myo-
cardial infarction.1,2 As compared with bare-metal 
stents, drug-eluting stents reduce neointimal hy-
perplasia and have been shown in large, random-
ized trials to be safe and effective for the treat-
ment of simple lesions in patients with stable 
coronary-artery disease.3,4 As would be expected, 
however, the rates of target-lesion revasculariza-
tion, stent thrombosis, and death are increased 
when drug-eluting stents are used in higher-risk 
patients and those with more complex lesions.5,6 
Specifically, when drug-eluting stents are implant-
ed in ruptured plaques with a large necrotic core 
(the lesion substrate responsible for most cases 
of ST-segment elevation myocardial infarction),7 
they may impair vascular healing responses, po-
tentially resulting in increased rates of stent 
thrombosis.8,9 Reduced rates of target-lesion revas-
cularization with drug-eluting stents, as compared 
with bare-metal stents, in patients with ST-seg-
ment elevation myocardial infarction have been 
reported in small-to-moderate-size randomized 
trials10; none, however, were powered for safety 
end points, and the routine performance of fol-
low-up angiography may have exaggerated the 
benefits of drug-eluting stents in many of these 
studies.11,12
To address these limitations, we performed a 
large-scale, international, prospective, random-
ized trial comparing paclitaxel-eluting stents with 
bare-metal stents in patients with evolving ST-
segment elevation myocardial infarction. The 
study was powered for safety as well as efficacy, 
with follow-up angiographic assessment per-
formed only after the primary clinical end point 
had been evaluated.
Me thods
Study Design
The Harmonizing Outcomes with Revasculariza-
tion and Stents in Acute Myocardial Infarction 
(HORIZONS-AMI) trial was a prospective, open-
label, multicenter, controlled trial involving pa-
tients with ST-segment elevation myocardial in-
farction who were undergoing primary PCI as a 
management strategy. The study incorporated two 
factorial randomized phases to allow a compari-
son of the direct thrombin inhibitor bivalirudin 
alone with heparin plus glycoprotein IIb/IIIa in-
hibitors and a comparison of paclitaxel-eluting 
stents with bare-metal stents.13,14 The trial was 
designed by the principal investigator, executive 
committee, and pharmacology committee and was 
sponsored and managed by the Cardiovascular Re-
search Foundation, a nonprofit foundation affili-
ated with Columbia University, with grant support 
from Boston Scientific Corporation and the Med-
icines Company. Other than supplying financial 
support and the drugs and devices, the funding 
companies were not involved with study processes, 
including site selection and management, data col-
lection, and analysis. The principal investigator had 
unrestricted data access after the database was 
locked, controlled the decision to submit the find-
ings for publication, prepared the manuscript, and 
vouches for the integrity of the data. 
Patient Population and Randomization
Consecutive patients 18 years of age or older who 
presented within 12 hours after the onset of symp-
toms and who had ST-segment elevation of 1 mm 
or more in two or more contiguous leads, new left 
bundle-branch block, or true posterior myocar-
dial infarction were considered for enrollment. 
The clinical exclusion criteria, which have been 
described previously, were contraindications to 
study medications, conditions that increase the 
risk of hemorrhage, and an inability to take clopid-
ogrel for 6 months after the procedure.13,14 The 
study was approved by the institutional review 
board or ethics committee at each participating 
center, and all patients gave written informed 
consent.
Eligible patients were randomly assigned in a 
1:1 ratio to treatment with unfractionated hepa-
rin plus a glycoprotein IIb/IIIa inhibitor or to 
treatment with bivalirudin alone (Fig. 1); the tim-
ing and dosing for each regimen have been de-
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scribed previously.13,14 After the first randomiza-
tion, emergency coronary angiography with left 
ventriculography was performed, and patients 
were then assigned, at the discretion of the phy-
sician, to treatment with PCI or coronary-artery 
bypass grafting (CABG) or to medical manage-
ment. Among patients undergoing PCI, anatomi-
cal eligibility for randomization to stent implan-
tation was assessed after the restoration of patency 
in the infarct-related vessel (by means of sponta-
neous reperfusion, guidewire recanalization, or 
inflation of an undersized angioplasty balloon). 
33p9
3602 Patients with STEMI underwent
randomization for pharmacologic phase
Emergency angiography
1802 Were assigned to heparin plus
 glycoprotein IIb/IIIa inhibitors
2257 Were assigned to paclitaxel-
eluting stents
749 Were assigned to bare-metal
stents
715 Were included in 1-yr
follow-up
1800 Were assigned to bivalirudin
alone
193 Received primary medical
therapy
62 Underwent CABG
2 Had PCI deferred
339 Underwent PCI but were not
eligible for stent phase
119 Underwent balloon angio-
plasty only
220 Received stents but were
excluded for other reasons
2186 Were included in 1-yr
follow-up
3006 Underwent randomization
for stent phase
7 Withdrew
27 Were lost to follow-up
18 Withdrew
53 Were lost to follow-up
AUTHOR:
FIGURE:
JOB: ISSUE:
4-C
H/T
RETAKE
SIZE
ICM
CASE
EMail Line
H/T
Combo
Revised
AUTHOR, PLEASE NOTE: 
Figure has been redrawn and type has been reset.
Please check carefully.
REG F
Enon
1st
2nd
3rd
Stone
1 of 2
05-07-09
ARTIST: ts
36019
Figure 1. Randomization, Treatment, and Follow-up at 1 Year.
Patients with ST-segment elevation myocardial infarction (STEMI) were included if they presented within 12 hours 
after the onset of symptoms. Of the 3226 patients undergoing primary stenting, 220 were not randomly assigned to 
a stent group for the following reasons: the absence of any eligible vessels (85 patients), excessive tortuosity or calcifi-
cation (35), bifurcation lesion with planned dual-branch stenting (2 ), unprotected left main coronary artery lesion 
(13), anticipated stent length of more than 100 mm (8), infarct lesion due to stent thrombosis (11), coronary-artery 
bypass grafting (CABG) likely to be performed within 30 days (37), lesions otherwise ineligible (29), and other or 
 unspecified reasons (28). More than one reason was present for some patients. PCI denotes percutaneous coronary 
intervention.
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Patients were considered to be eligible for random 
assignment to paclitaxel-eluting stents or bare-
metal stents if an acute-infarct–related artery was 
present in which all lesions requiring PCI had a 
visually estimated reference-vessel diameter be-
tween 2.25 mm and 4.0 mm, without excessive 
tortuosity or severe calcification. Angiographic 
exclusion criteria were planned stenting of an un-
protected left main artery (i.e., a left main artery 
without a patent bypass graft to either the left an-
terior descending artery or the left circumflex ar-
tery), a bifurcation lesion that required planned 
implantation of stents in both the main vessel and 
a side branch (bifurcation lesions were included 
if a single-stent strategy was intended, even if mul-
tiple stents were ultimately required), an antici-
pated stent length of more than 100 mm, infarc-
tion due to stent thrombosis, and an anticipated 
need for bypass grafting within 30 days. Patients 
with multiple lesions and vessels requiring inter-
vention were included in the study if all the le-
sions were eligible for study stents.
Patients who were eligible for random assign-
ment to stent implantation were assigned in a 
3:1 ratio to receive either paclitaxel-eluting stents 
(TAXUS Express, Boston Scientific) or otherwise 
identical bare-metal stents (Express, Boston Sci-
entific) (Fig. 1). Randomization was performed 
with the use of a computerized, interactive voice-
response system and a dynamic (minimization) 
allocation scheme that balanced the assignment 
for the pharmacologic assignment (unfractionat-
ed heparin plus a glycoprotein IIb/IIIa inhibitor 
or bivalirudin alone), the presence or absence of 
diabetes mellitus, lesion length (>26 mm, requir-
ing overlapping stents, vs. ≤26 mm), and location 
of the study site (in the United States or outside 
the United States).
Protocol Procedures
Stents with a diameter between 100 and 110% of 
the distal reference-vessel diameter were implant-
ed, and implantation was performed with a min-
imum pressure of 14 atm. Direct stenting (i.e., 
without balloon predilation) was permitted ac-
cording to the discretion of the physician if the 
infarct-related vessel was patent (i.e, had a Throm-
bolysis in Myocardial Infarction [TIMI] f low 
grade of 2 or 3) at baseline. Study stents were 
available in diameters ranging from 2.25 to 4.0 mm 
and in lengths ranging from 8 to 32 mm.
Aspirin (324 mg administered in chewable 
form or 500 mg administered intravenously) was 
given in the emergency room, after which 300 to 
325 mg was given orally every day during the 
hospitalization and 75 to 81 mg every day there-
after indefinitely. A loading dose of clopidogrel 
(either 300 mg or 600 mg, at the discretion of 
the investigator) was administered before cathe-
terization, followed by 75 mg orally every day for 
at least 6 months (with a recommendation of 
1 year or longer).
Clinical follow-up examinations were performed 
at 30 days, 6 months, and 12 months, and then 
yearly for a total of 5 years. The primary clinical 
end points of the first randomization (pharmaco-
logic phase) were prespecified at 30 days, where-
as the primary end points of the second ran-
domization (stent phase) were prespecified at 12 
months. Routine angiographic follow-up at 13 
months (after ascertainment of the primary 12-
month clinical end points) was prespecified for 
1800 patients randomly assigned to receive a stent 
in whom implantation of the stent was success-
ful (diameter stenosis <10% with a TIMI flow 
grade of 3 and a National Heart, Lung, and Blood 
Institute classification for coronary-artery dissec-
tion of type A or less adjacent to the stent), stent 
thrombosis did not occur, and bypass grafting 
was not performed within 30 days after implan-
tation of the stent.
Statistical Analysis
Two primary 12-month clinical end points were 
prespecified: ischemia-driven revascularization of 
the target lesion and a composite safety end point 
of major adverse cardiovascular events, consisting 
of death, reinfarction, stroke, and stent throm-
bosis. The components of the safety end point 
have been defined previously.13,14 Target-lesion 
revascularization was considered to be ischemia-
driven if there was stenosis of at least 50% of the 
diameter of the target lesion, as documented by 
a positive functional study, ischemic changes on 
an electrocardiogram, or symptoms referable to 
the target lesion, or in the absence of document-
ed ischemia, if there was stenosis of at least 70% 
as assessed by quantitative coronary analysis at 
the independent core laboratory. Stent thrombo-
sis was defined as the definite or probable occur-
rence of a thrombotic event, according to the Aca-
demic Research Consortium classification.15 An 
independent clinical events committee whose 
members were unaware of the treatment assign-
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ments adjudicated all primary end-point events 
by reviewing original source documents and pro-
cedural angiograms. Angiographic analysis was 
performed at the core laboratory with the use of 
validated methods by technicians who were un-
aware of the treatment assignments and clinical 
outcomes.16
The trial was powered to show the superiority 
of paclitaxel-eluting stents as compared with 
bare-metal stents for the 12-month primary effi-
cacy end point of target-lesion revascularization 
and the major secondary efficacy end point of 
binary restenosis as assessed by angiography at 
13 months, with a two-sided alpha level of 0.05. 
Assuming 1-year rates of ischemia-driven target-
lesion revascularization of 5.0% in the paclitaxel-
eluting–stent group and 9.0% in the bare-metal–
stent group, with assignment of 2250 patients 
and 750 patients to the two groups, respectively, 
and 95% of the patients available for the 1-year 
follow-up, we calculated that the trial would have 
95% power to show the superiority of paclitaxel-
eluting stents for the primary efficacy end point. 
Assuming that 1200 patients had follow-up an-
giograms at 13 months that could be evaluated, 
the trial would have 96% power to show a reduc-
tion in binary restenosis from 26.0% with bare-
metal stents to 15.6% with paclitaxel-eluting 
stents. The trial was also powered to show the 
noninferiority of paclitaxel-eluting stents as com-
pared with bare-metal stents for the primary 
composite safety end point of major adverse car-
diovascular events, on the basis of the upper 
boundary of the two-sided 95% confidence inter-
Table 1. Baseline Characteristics of the Study Patients and Medication Use.
Variable
Paclitaxel-Eluting  
Stents (N = 2257)
Bare-Metal  
Stents (N = 749) P Value
Age — yr   0.26
Median 59.9 59.3
Range 30.9–92.3 26.0–89.0
Male sex — no. (%) 1738 (77.0) 569 (76.0) 0.56
Diabetes — no./total no. (%)
Any 364/2256 (16.1) 114/749 (15.2) 0.55
Insulin-requiring 98/2256 (4.3) 31/749 (4.1) 0.81
Hypertension — no./total no. (%) 1155/2256 (51.2) 389/749 (51.9) 0.73
Hyperlipidemia — no./total no. (%) 953/2256 (42.2) 308/749 (41.1) 0.59
Current smoker — no./total no. (%) 1041/2246 (46.3) 388/748 (51.9) 0.009
Prior myocardial infarction — no./total no. (%) 206/2256 (9.1) 82/749 (10.9) 0.14
Prior percutaneous coronary intervention — no./total no. (%) 214/2255 (9.5) 58/749 (7.7) 0.15
Prior coronary-artery bypass grafting — no./total no. (%) 50/2256 (2.2) 14/749 (1.9) 0.57
Time from symptom onset to balloon inflation — min 0.36
Median 221 225
Interquartile range 160–329 162–350
Time from arrival at hospital to balloon inflation — min 0.92
Median 100 97
Interquartile range 74–134 71–138
Killip class II, III, or IV — no./total no. (%) 199/2254 (8.8) 60/748 (8.0) 0.50
Renal insufficiency — no./total no. (%)* 328/2102 (15.6) 107/696 (15.4) 0.88
Anemia — no./total no. (%)† 235/2130 (11.0) 54/715 (7.6) 0.008
Thrombocytopenia — no./total no. (%)‡ 91/2186 (4.2) 30/733 (4.1) 0.93
Left ventricular ejection fraction — %§  0.49
Median 50 50
Interquartile range 44–59 43–58
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val for the difference in percentages, with a non-
inferiority margin of 3.0%. Assuming a 7.5% rate 
of the safety end point of major adverse cardio-
vascular events in both stent groups, we calcu-
lated that the study would have 80% power to 
show the noninferiority of paclitaxel-eluting stents 
as compared with bare-metal stents for the pri-
mary safety end point.
Data were analyzed according to the group as-
signment, regardless of the treatment received. 
Categorical outcomes were compared by means 
of the chi-square test or Fisher’s exact test. Con-
tinuous variables were compared by means of 
the Wilcoxon rank-sum test. The primary event 
analyses were performed with the use of time-
to-event data (with data censored at the time of 
a patient’s withdrawal from the study or at the 
last follow-up examination); the results of these 
analyses are shown with the use of Kaplan–
Meier methods and were compared by means of 
the log-rank test. As a secondary analysis, time-
updated Cox proportional-hazards regression with 
adjustment for covariates was performed to ad-
just for baseline imbalances and differences in 
medication use between the groups over time.
R esult s
Patients and Procedures
Between March 25, 2005, and May 7, 2007, a total 
of 3602 patients with ST-segment elevation myo-
cardial infarction who were undergoing primary 
PCI at 123 centers in 11 countries were randomly 
assigned to treatment with heparin plus a glyco-
Table 1. (Continued.)
Variable
Paclitaxel-Eluting  
Stents (N = 2257)
Bare-Metal  
Stents (N = 749) P Value
Use of antithrombin during PCI — no./total no. (%)
Unfractionated heparin 1123/2255 (49.8) 375/749 (50.1) 0.90
Bivalirudin 1141/2252 (50.7) 379/745 (50.9) 0.92
Use of glycoprotein IIb/IIIa inhibitor during PCI — no./total 
no. (%)
1171/2253 (52.0) 385/748 (51.5) 0.81
Medications at discharge — no./total no. (%)
Beta-blockers 2048/2213 (92.5) 680/738 (92.1) 0.72
Angiotensin-converting–enzyme inhibitors or receptor 
blockers
1840/2212 (83.2) 614/738 (83.2) 0.99
Statins 2123/2212 (96.0) 708/738 (95.9) 0.96
Use of aspirin — no./total no. (%)
At discharge 2192/2213 (99.1) 728/738 (98.6) 0.35
At 30 days¶ 2115/2148 (98.5) 700/712 (98.3) 0.78
At 6 mo¶ 2043/2096 (97.5) 682/694 (98.3) 0.23
At 1 yr¶ 2019/2080 (97.1) 662/679 (97.5) 0.56
Use of thienopyridine — no./total no. (%)
At discharge 2200/2213 (99.4) 730/738 (98.9) 0.16
At 30 days¶ 2127/2154 (98.7) 696/712 (97.8) 0.06
At 6 mo¶ 1989/2100 (94.7) 607/694 (87.5) <0.001
At 1 yr¶ 1522/2083 (73.1) 434/679 (63.9) <0.001
* Renal insufficiency was defined as a creatinine clearance of less than 60 ml per minute as calculated with the use of the 
Cockcroft–Gault equation.
† Anemia was defined, according to the World Health Organization criteria, as a hematocrit value at initial presentation 
of less than 39% for men and less than 36% for women.
‡ Thrombocytopenia was defined as less than 150,000 platelets per cubic millimeter.
§ The left ventricular ejection fraction was assessed visually on the contrast-enhanced left ventriculogram obtained at 
baseline.
¶ Patients were considered to have used aspirin or a thienopyridine if they had taken the drug on more than 50% of the 
days since the previous study visit.
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protein IIb/IIIa inhibitor (1802 patients) or to 
treatment with bivalirudin alone (1800 patients) 
(Fig. 1). PCI was subsequently performed in 3345 
patients (92.9%), of whom 3226 (96.4%) underwent 
attempted stenting. Among those patients under-
going primary stenting, 3006 (93.2%) were ran-
domly assigned to receive either paclitaxel-eluting 
stents (2257 patients) or bare-metal stents (749). 
A total of 220 patients received stents but were 
not randomly assigned to a study group for a va-
riety of reasons (Fig. 1).
The baseline features of the groups were well 
matched, except that there was a slightly higher 
percentage of current smokers in the group as-
signed to receive bare-metal stents and a slightly 
higher percentage of patients with baseline ane-
mia in the group assigned to receive paclitaxel-
eluting stents (Table 1). The median age of the 
patients was 59.7 years, and 76.7% of the patients 
were men. The angiographic characteristics and 
procedural results were also similar between the 
groups except that the lesions in the patients as-
signed to receive paclitaxel-eluting stents were 
slightly longer, necessitating the use of slightly 
longer stents (Table 2). Compliance with taking 
aspirin was high in both groups throughout the 
12-month follow-up period. The rate of thienopyri-
dine use was slightly higher at 6 and 12 months 
among patients in whom paclitaxel-eluting stents 
had been implanted than among those in whom 
bare-metal stents had been implanted.
Clinical Outcomes
The rate of the primary efficacy end point, ische-
mia-driven target-lesion revascularization at 12 
months, was 4.5% in the paclitaxel-eluting–stent 
group as compared with 7.5% in the bare-metal–
stent group (hazard ratio with paclitaxel-eluting 
stents, 0.59; 95% confidence interval [CI], 0.43 to 
0.83), which represented a benefit for 3 addition-
al patients per 100 who were treated for 1 year 
with paclitaxel-eluting stents as compared with 
bare-metal stents (95% CI, 0.9 to 5.1; P = 0.002) 
and a 41% relative hazard reduction with pacli-
taxel-eluting stents as compared with bare-metal 
stents (Table 3 and Fig. 2). The rate of ischemia-
driven target-vessel revascularization at 12 months 
was also lower among patients treated with pacli-
taxel-eluting stents than among those treated with 
bare-metal stents (5.8% vs. 8.7%; hazard ratio, 
0.65; 95% CI, 0.48 to 0.89; P = 0.006). The 12-month 
rates of the primary safety end point of major 
adverse cardiovascular events were similar between 
patients who received paclitaxel-eluting stents and 
those who received bare-metal stents (8.1% and 
8.0%, respectively; hazard ratio with paclitaxel-
eluting stents, 1.02; 95% CI, 0.76 to 1.36; absolute 
difference, 0.1 percentage point; 95% CI, −2.1 to 
2.4; P = 0.01 for noninferiority; P = 0.92 for superi-
ority). The individual rates of death, reinfarction, 
stroke, and stent thrombosis were also similar in 
the two groups through 12 months of follow-up. 
The point estimates for the two primary end 
points were not significantly changed after cor-
rection for the baseline differences in smoking 
and anemia and follow-up use of thienopyridine 
agents (hazard ratio for ischemic target-lesion 
revascularization with paclitaxel-eluting stents, 
0.62; 95% CI, 0.44 to 0.87; P = 0.006; hazard ratio 
for major adverse cardiovascular events, 1.03; 
95% CI, 0.76 to 1.40; P = 0.84). In logistic-regres-
sion analyses, there were no significant interac-
tions between the initial pharmacologic group 
assignment (heparin plus a glycoprotein IIb/IIIa 
inhibitor or bivalirudin alone) and the assigned 
stent type with respect to the occurrence of the 
two primary end points (P = 0.17 for ischemic tar-
get-lesion revascularization and P = 0.89 for ma-
jor adverse cardiovascular events).
Angiographic Outcomes
Angiographic follow-up data at 13 months were 
available for 910 patients who received paclitaxel-
eluting stents (1081 lesions) and for 293 patients 
who received bare-metal stents (332 lesions) and 
were analyzed at the core angiographic labora-
tory. The rate of the major secondary efficacy end 
point, analysis-segment binary restenosis (which 
includes measurements within the stent and 5 mm 
proximal and distal to the stent) in all lesions, 
was 10.0% among lesions in the paclitaxel-eluting–
stent group as compared with 22.9% among le-
sions in the bare-metal–stent group, a difference 
of 56% (relative risk with paclitaxel-eluting stents, 
0.44; 95% CI, 0.33 to 0.57; P<0.001). Among the 
1062 lesions in the paclitaxel-eluting–stent group 
and the 328 in the bare-metal–stent group in 
which stents were implanted (Table 4), in-stent 
late luminal loss was less with paclitaxel-eluting 
stents than with bare-metal stents (0.41±0.64 mm 
vs. 0.82±0.70 mm, P<0.001), and the rate of analy-
sis-segment binary restenosis was lower (9.6% vs. 
23.2%, P<0.001). There were no significant dif-
ferences in the rates of reocclusion of the infarct-
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Table 2. Angiographic and Procedural Outcomes.*
Variable
Paclitaxel-Eluting 
Stents (N = 2257)
Bare-Metal 
Stents (N = 749) P Value
Lesions treated 0.12
Total no. 2525 820
No. per patient 1.1±0.4 1.1±0.4
≥2 lesions treated — no. of patients/total no. (%) 248/2236 (11.1) 67/742 (9.0) 0.11
≥2 vessels treated — no. of patients/total no. (%) 101/2236 (4.5) 23/742 (3.1) 0.09
Type of stent — no. of lesions/total no. (%)
Paclitaxel-eluting 2485/2525 (98.4) 1/820 (0.1) —
Other drug-eluting 0/2525 1/820 (0.1) —
Bare-metal 28/2525 (1.1) 813/820 (99.1) —
Site of infarct lesion — no. of lesions/total no. (%)
Left anterior descending coronary artery 1006/2525 (39.8) 347/820 (42.3) 0.21
Left circumflex coronary artery 374/2525 (14.8) 132/820 (16.1) 0.37
Right coronary artery 1138/2525 (45.1) 338/820 (41.2) 0.05
Left main coronary artery 7/2525 (0.3) 3/820 (0.4) 0.71
Saphenous-vein graft 30/2498 (1.2) 6/811 (0.7) 0.27
Implantation of at least one stent attempted  
— no. of lesions/total no. (%)
2501/2525 (99.0) 815/820 (99.4) 0.36
Direct stenting attempted  
— no. of lesions/total no. (%)†
734/2501 (29.3) 264/815 (32.4) 0.10
No. of stents implanted per patient 1.5±0.9 1.4±0.7 <0.001
Total stent length per patient — mm 30.8±17.8 27.3±14.9 <0.001
Maximum balloon diameter per lesion — mm 3.20±0.61 3.18±0.58 0.84
Maximum pressure per lesion — atm 14.9±3.5 14.9±3.3 0.98
Aspiration catheter used — no. of patients/total no. (%) 255/2246 (11.4) 80/745 (10.7) 0.64
Baseline TIMI flow grade — no. of vessels/total no. (%)‡
0 or 1 1424/2348 (60.6) 442/770 (57.4) 0.11
2 320/2348 (13.6) 117/770 (15.2) 0.28
3 604/2348 (25.7) 211/770 (27.4) 0.36
Baseline quantitative angiographic findings for lesions
Reference-vessel diameter — mm 2.89±0.51 2.90±0.50 0.75
Minimal luminal diameter — mm 0.35±0.45 0.35±0.45 0.81
Stenosis — % of vessel diameter 87.6±15.4 87.4±15.4 0.83
Lesion length — mm 17.5±10.1 16.2±8.8 0.006
Final TIMI flow grade — no. of vessels/total no. (%)
0 or 1 40/2346 (1.7) 7/771 (0.9) 0.12
2 252/2346 (10.7) 72/771 (9.3) 0.27
3 2054/2346 (87.6) 692/771 (89.8) 0.10
Final quantitative angiographic findings for lesions
Reference-vessel diameter — mm 2.93±0.51 2.95±0.50 0.57
Minimal luminal diameter — mm 2.36±0.55 2.37±0.52 0.38
Stenosis — % of vessel diameter 19.9±11.6 19.5±11.1 0.33
* Plus–minus values are means ±SD. TIMI denotes Thrombolysis in Myocardial Infarction.
† Direct stenting refers to the implantation of a stent without balloon predilation.
‡ TIMI flow is graded on a scale of 0 to 3, with a higher grade indicating better flow.
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related artery (TIMI flow grade of 0 or 1), ulcer-
ation, ectasia, or aneurysm formation between the 
two stent groups.
Discussion
In this international, prospective, controlled trial 
involving patients with ST-segment elevation myo-
cardial infarction who were undergoing primary 
PCI, in which more than 93% of the patients who 
received stents were randomly assigned to a study-
stent group, treatment with paclitaxel-eluting stents 
as compared with otherwise identical bare-metal 
stents resulted in a significantly reduced rate of 
angiographically assessed restenosis and in a sig-
nificantly decreased rate of recurrent ischemia ne-
cessitating repeat revascularization by means of 
PCI or CABG. Moreover, paclitaxel-eluting stents 
were noninferior to bare-metal stents with respect 
to the primary composite safety end point of major 
adverse cardiovascular events at 12 months, with 
similar rates of the individual components of the 
composite safety end point (i.e., death, reinfarction, 
stroke, and stent thrombosis). The HORIZONS-AMI 
trial thus provides data indicating that paclitaxel-
eluting stents can be used in patients with evolv-
ing ST-segment elevation myocardial infarction.
A meta-analysis of previous small-to-moderate-
size randomized trials showed that for each 1000 
patients with ST-segment elevation myocardial in-
farction who received drug-eluting stents as com-
pared with bare-metal stents, approximately 76 
fewer required target-vessel revascularization with-
in 1 year.10 In contrast, in our trial, in which more 
Table 3. Clinical Outcomes at 1 Year.*
Outcome Cumulative No. of Events
Kaplan–Meier Estimate  
of Cumulative Event-Rate P Value
Paclitaxel-Eluting  
Stents (N = 2257)
Bare-Metal 
Stents (N = 749)
Paclitaxel-Eluting 
Stents (N = 2257)
Bare-Metal 
Stents (N = 749)
Ischemia-driven target-lesion revascularization† 98 54 4.5 7.5 0.002
PCI 88 48 4.0 6.6 0.004
CABG 10 7 0.5 1.0 0.12
Ischemia-driven target-vessel revascularization‡ 126 63 5.8 8.7 0.006
PCI 109 56 5.0 7.7 0.006
CABG 18 8 0.8 1.1 0.48
Major adverse cardiovascular events§ 181 59 8.1 8.0 0.92
Death 78 26 3.5 3.5 0.98
Cardiac 54 20 2.4 2.7 0.67
Noncardiac 24 6 1.1 0.8 0.55
Reinfarction 81 33 3.7 4.5 0.31
Q-wave 45 14 2.0 1.9 0.83
Non–Q-wave 39 19 1.8 2.7 0.16
Death or reinfarction 152 52 6.8 7.0 0.83
Stroke 23 5 1.0 0.7 0.39
Stent thrombosis¶ 70 25 3.2 3.4 0.77
Definite 58 22 2.6 3.0 0.60
Probable 12 3 0.5 0.4 0.65
* CABG denotes coronary-artery bypass grafting, and PCI percutaneous coronary intervention.
† Ischemia-driven target-lesion revascularization (the primary efficacy end point) refers to a procedure to treat recurrent ischemia due to  
restenosis at the site of the original target lesion (including a 5-mm proximal or distal margin outside the stent).
‡ Ischemia-driven target-vessel revascularization refers to a procedure to treat recurrent ischemia due either to restenosis within or just out-
side the stent or to a lesion anywhere else in the same epicardial coronary artery or its branches.
§ The composite primary safety end point of major adverse cardiovascular events comprised death, myocardial infarction, stroke, and stent 
thrombosis.
¶ Stent thrombosis was defined according to the Academic Research Consortium classification.15
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than 3000 patients were randomly assigned to a 
stent group, approximately 30 fewer per 1000 pa-
tients who received paclitaxel-eluting stents as 
compared with a bare-metal stents required target-
vessel revascularization within 1 year. Since rela-
tively few patients were excluded from our trial 
because of anatomical complexity, the most likely 
explanation for the differences between these 
findings is that routine angiographic follow-up 
was performed before the assessment of the pri-
mary clinical end point in most of the earlier 
randomized trials, a protocol-specific process 
that artificially increases the rates of revascular-
ization (the “oculostenotic reflex”).11,12 In con-
trast, routine angiographic follow-up in the pres-
ent trial was not performed until 1 month after 
ascertainment of the primary 12-month clinical 
end points, thereby permitting a more accurate 
and realistic determination of treatment-related 
effects. Also, in the present study, the 41% rela-
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Figure 2. Kaplan–Meier Time-to-Event Curves for Primary End Points and Three Components of the Primary Composite Safety End Point.
Time-to-event curves through 1 year are shown for ischemia-driv n target-lesion revascularization (TLR) (Panel A), the composite safety 
end point of major adverse cardiovascular events (MACE), consisting of death, reinfarction, stroke, and stent thrombosis (Panel B), death 
or reinfarction (Panel C), and stent thrombosis (definite or probable, defined according to the Academic Research Consortium classifica-
tion) (Panel D). Treatment with paclitaxel-eluting stents as compared with bare-metal stents resulted in a lower 12-month rate of ischemia-
driven target-lesion revascularization (4.5% vs. 7.5%; hazard ratio, 0.59; 95% CI, 0.43 to 0.83; P = 0.002), a noninferior 12-month rate of 
the safety composite end point of major adverse cardiovascular events (8.1% vs. 8.0%; hazard ratio, 1.02; 95% CI, 0.76 to 1.36; P=0.01 
for noninferiority; P = 0.92 for superiority), and nonsignificantly different 12-month rates of death or reinfarction (6.8% vs. 7.0%; hazard 
ratio, 0.97; 95% CI, 0.70 to 1.32; P = 0.83) and of stent thrombosis (3.2% vs. 3.4%; hazard ratio, 0.93; 95% CI, 0.59 to 1.47; P = 0.77).
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tive hazard reduction in the rate of clinically 
assessed restenosis (ischemia-driven target-lesion 
revascularization) at 12 months with paclitaxel-
eluting stents as compared with bare-metal stents 
was somewhat less than the 56% relative reduc-
tion in the rate of angiographically assessed reste-
nosis at 13 months. This difference may be due 
to the occasional occurrence of restenosis that 
does not provoke ischemia or symptoms in an 
infarcted myocardial territory. This possibility, 
coupled with the elimination of unnecessary re-
vascularization procedures because we did not 
perform routine angiographic follow-up before 
assessing the primary clinical end point, explains 
the relatively low 1-year rate of ischemia-driven 
target-lesion revascularization after implantation 
of bare-metal stents that was observed in the 
present trial. Longer-term follow-up will show 
whether the marked reduction in angiographical-
ly assessed restenosis with paclitaxel-eluting stents 
as compared with bare-metal stents results in 
greater incremental clinical benefits beyond 12 
months.
The results of the present study are otherwise 
consistent with those of earlier, smaller, random-
ized studies, in which 1-year mortality rates were 
similar between patients with ST-segment eleva-
tion myocardial infarction who were treated with 
drug-eluting stents and those who were treated 
with bare-metal stents.10 In contrast, in large, 
nonrandomized, observational studies of data 
from state registries in Massachusetts, New York, 
and New Jersey, in which multivariable and 
propensity-score adjustments were used to correct 
for measured baseline differences, the results 
suggested that drug-eluting stents, as compared 
with bare-metal stents, significantly reduce mor-
tality among patients with ST-segment elevation 
Table 4. Angiographic Findings at 13 Months.*
Finding
Paclitaxel-Eluting 
Stents
Bare-Metal 
Stents P Value
TIMI flow grade — no. of vessels/total no. (%)
0 or 1 27/964 (2.8) 11/302 (3.6) 0.45
2 67/964 (7.0) 15/302 (5.0) 0.22
3 870/964 (90.2) 276/302 (91.4) 0.55
Quantitative coronary angiography of lesions†
Reference-vessel diameter — mm 2.91±0.48 2.90±0.48 0.94
Minimal luminal diameter — mm
In-stent 2.36±0.75 1.98±0.82 <0.001
In-segment 2.09±0.68 1.84±0.76 <0.001
Late loss — mm
In-stent 0.41±0.64 0.82±0.70 <0.001
In-segment 0.30±0.56 0.59±0.64 <0.001
Stenosis — % of vessel diameter
In-stent 18.7±22.8 32.6±24.9 <0.001
In-segment 28.6±19.4 37.4±22.1 <0.001
Binary restenosis — no. of lesions/total no. (%)
In-stent 87/1062 (8.2) 69/328 (21.0) <0.001
In-segment 102/1062 (9.6) 76/328 (23.2) <0.001
Aneurysm formation — no. of lesions/total no. (%)† 4/1059 (0.4) 3/328 (0.9) 0.37
Ulceration — no. of lesions/total no. (%)† 5/1060 (0.5) 2/328 (0.6) 0.67
Ectasia — no. of lesions/total no. (%)† 7/1059 (0.7) 3/328 (0.9) 0.71
* Plus–minus values are means ±SD. TIMI denotes Thrombolysis in Myocardial Infarction.
† Data are for stented lesions only; no stent was implanted in 15 lesions in the paclitaxel-eluting–stent group and 4 lesions 
in the bare-metal–stent group.
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myocardial infarction.17-19 However, scrutiny of 
the hazard curves in these registry studies indi-
cates that much of the relative survival benefit 
with drug-eluting stents occurred within 30 days 
after stent implantation, before the known bene-
fits of drug-eluting stents in reducing restenosis 
are apparent. The inability to adjust for unmea-
sured confounders (including coexisting condi-
tions and other factors that make noncompliance 
with clopidogrel therapy likely in patients selected 
to receive bare-metal stents) probably explains the 
observed reduction in mortality with drug-eluting 
stents in these nonrandomized studies. In con-
trast, the results of randomized trials that now 
include more than 6500 patients strongly suggest 
that survival within 1 year after implantation is 
similar, but not improved, with drug-eluting stents 
as compared with bare-metal stents among pa-
tients with ST-segment elevation myocardial in-
farction. Similarly, the present trial confirms and 
extends the results of earlier randomized stud-
ies10 that showed similar rates of stent thrombo-
sis and reinfarction at 1 year with drug-eluting 
stents and bare-metal stents in patients with ST-
segment elevation myocardial infarction.
Several limitations of the present study deserve 
comment. First, logistic complexities necessitated 
an open-label design. Potential bias was mitigated 
by high rates of compliance with the protocol pro-
cedures and the use of blinded clinical-event ad-
judication and core-laboratory assessments. Sec-
ond, although the rate of use of thienopyridine 
agents was slightly greater between 6 and 12 
months in the group that received paclitaxel-elut-
ing stents than in the group that received bare-
metal stents, the point estimates for the primary 
efficacy and safety end points were not signifi-
cantly altered after multivariable adjustment for 
this imbalance. Third, although the nearly iden-
tical rates of the safety end point of major adverse 
cardiovascular events in the two stent groups sug-
gest that paclitaxel-eluting stents are safe in pa-
tients with evolving ST-segment elevation myocar-
dial infarction at 1 year, longer-term follow-up is 
required to characterize the late safety and effi-
cacy profiles of paclitaxel-eluting stents in patients 
with ST-segment elevation myocardial infarction, 
especially as the use of dual antiplatelet agents 
declines over time after stent implantation. This 
point is particularly germane because the in-
creased risk of stent thrombosis with drug-eluting 
stents as compared with bare-metal stents may 
emerge only beyond 1 year after stent implanta-
tion3 and because at least one previous study20 
(but not all17-19,21) has suggested that the incre-
mental benefits of drug-eluting stents in patients 
with ST-segment elevation myocardial infarction 
diminish with late follow-up. Fourth, although the 
present trial had relatively few exclusion criteria, 
the results apply only to patients who were en-
rolled; specifically, patients with unprotected left 
main coronary artery disease, patients with bifur-
cation lesions requiring planned dual-stent treat-
ment, and patients who were unlikely to comply 
with at least 6 months of dual antiplatelet therapy 
were excluded, and relatively few patients with 
cardiogenic shock were enrolled. Further studies 
are also required to determine which patients and 
lesions are most likely to benefit from drug-elut-
ing stents, the long-term safety of drug-eluting 
stents after discontinuation of thienopyridine treat-
ment, and the relative cost-effectiveness of such 
stents in patients with ST-segment elevation myo-
cardial infarction, all of which are important con-
siderations in deciding which type of stent to use 
during primary PCI. Finally, our findings apply 
only to paclitaxel-eluting stents; future large-scale 
trials are required to determine the relative safety 
and efficacy of other drug-eluting stents in pa-
tients with ST-segment elevation myocardial in-
farction, especial ly stents that are more potent in-
hibitors of neo intimal proliferation.22,23
In conclusion, the present trial shows that in 
patients with evolving ST-segment elevation myo-
cardial infarction who are undergoing primary 
PCI with stent implantation, the use of paclitaxel-
eluting stents, as compared with bare-metal stents, 
reduces angiographic restenosis and recurrent 
ischemia necessitating repeat revascularization 
procedures within the first year. No safety con-
cerns were apparent at 1 year.
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